Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
GMED's Cash to Debt is ranked higher than
76% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. GMED: No Debt )
GMED' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.83
GMED's Equity to Asset is ranked higher than
86% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. GMED: 0.83 )
GMED' s 10-Year Equity to Asset Range
Min: 0.83   Max: 0.86
Current: 0.83

0.83
0.86
Interest Coverage No Debt
GMED's Interest Coverage is ranked higher than
91% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. GMED: No Debt )
GMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 17.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 23.40
GMED's Operating margin (%) is ranked higher than
95% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. GMED: 23.40 )
GMED' s 10-Year Operating margin (%) Range
Min: 23.4   Max: 30.43
Current: 23.4

23.4
30.43
Net-margin (%) 15.79
GMED's Net-margin (%) is ranked higher than
90% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. GMED: 15.79 )
GMED' s 10-Year Net-margin (%) Range
Min: 15.79   Max: 19.13
Current: 15.79

15.79
19.13
ROE (%) 14.53
GMED's ROE (%) is ranked higher than
89% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. GMED: 14.53 )
GMED' s 10-Year ROE (%) Range
Min: 14.53   Max: 21.52
Current: 14.53

14.53
21.52
ROA (%) 12.12
GMED's ROA (%) is ranked higher than
94% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. GMED: 12.12 )
GMED' s 10-Year ROA (%) Range
Min: 12.12   Max: 18.45
Current: 12.12

12.12
18.45
ROC (Joel Greenblatt) (%) 58.40
GMED's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. GMED: 58.40 )
GMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 58.4   Max: 69.93
Current: 58.4

58.4
69.93
» GMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

GMED Guru Trades in Q1 2013

Joel Greenblatt 11,069 sh (New)
Ronald Muhlenkamp 95,935 sh (New)
Steven Cohen 536,700 sh (+147.21%)
RS Investment Management 1,348,580 sh (+16.68%)
Chuck Royce 856,677 sh (+13.22%)
» More
Q2 2013

GMED Guru Trades in Q2 2013

Paul Tudor Jones 11,700 sh (New)
RS Investment Management 2,118,663 sh (+57.1%)
Ronald Muhlenkamp 96,150 sh (+0.22%)
Joel Greenblatt 10,113 sh (-8.64%)
Chuck Royce 770,677 sh (-10.04%)
Steven Cohen 438,514 sh (-18.29%)
» More
Q3 2013

GMED Guru Trades in Q3 2013

RS Investment Management 2,705,663 sh (+27.71%)
Steven Cohen 543,496 sh (+23.94%)
Paul Tudor Jones 13,300 sh (+13.68%)
Joel Greenblatt Sold Out
Ronald Muhlenkamp 93,805 sh (-2.44%)
Chuck Royce 601,677 sh (-21.93%)
» More
Q4 2013

GMED Guru Trades in Q4 2013

Joel Greenblatt 127,089 sh (New)
Jim Simons 273,600 sh (New)
Steven Cohen 1,016,020 sh (+86.94%)
Paul Tudor Jones 24,700 sh (+85.71%)
Ronald Muhlenkamp 112,875 sh (+20.33%)
Chuck Royce Sold Out
RS Investment Management 2,430,383 sh (-10.17%)
» More
» Details

Insider Trades

Latest Guru Trades with GMED

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2013-12-31 Add 20.33%0.07%$17.16 - $19.84 $ 23.7628%112875
Joel Greenblatt 2013-12-31 New Buy0.06%$17.16 - $19.84 $ 23.7628%127089
Joel Greenblatt 2013-09-30 Sold Out 0.01%$16.75 - $18.06 $ 23.7637%0
Ronald Muhlenkamp 2013-03-31 New Buy0.29%$10.49 - $15 $ 23.7677%95935
Joel Greenblatt 2013-03-31 New Buy0.01%$10.49 - $15 $ 23.7677%11069
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.50
GMED's P/E(ttm) is ranked higher than
56% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. GMED: 32.50 )
GMED' s 10-Year P/E(ttm) Range
Min: 12.95   Max: 36.02
Current: 32.5

12.95
36.02
P/B 4.69
GMED's P/B is ranked lower than
55% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. GMED: 4.69 )
GMED' s 10-Year P/B Range
Min: 2.45   Max: 5.2
Current: 4.69

2.45
5.2
P/S 5.15
GMED's P/S is ranked lower than
67% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. GMED: 5.15 )
GMED' s 10-Year P/S Range
Min: 2.48   Max: 5.71
Current: 5.15

2.48
5.71
PFCF 32.11
GMED's PFCF is ranked higher than
53% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. GMED: 32.11 )
GMED' s 10-Year PFCF Range
Min: 18.52   Max: 39.26
Current: 32.11

18.52
39.26
EV-to-EBIT 19.66
GMED's EV-to-EBIT is ranked higher than
66% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. GMED: 19.66 )
GMED' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 22.2
Current: 19.66

6.7
22.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.33
GMED's Price/Net Cash is ranked lower than
51% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 13.75 vs. GMED: 15.33 )
GMED' s 10-Year Price/Net Cash Range
Min: 6.32   Max: 13.02
Current: 15.33

6.32
13.02
Price/Net Current Asset Value 9.65
GMED's Price/Net Current Asset Value is ranked higher than
51% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 8.80 vs. GMED: 9.65 )
GMED' s 10-Year Price/Net Current Asset Value Range
Min: 4.21   Max: 8.2
Current: 9.65

4.21
8.2
Price/Tangible Book 5.23
GMED's Price/Tangible Book is ranked lower than
53% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. GMED: 5.23 )
GMED' s 10-Year Price/Tangible Book Range
Min: 2.65   Max: 4.44
Current: 5.23

2.65
4.44
Price/Median PS Value 1.31
GMED's Price/Median PS Value is ranked higher than
51% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. GMED: 1.31 )
GMED' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.11
Current: 1.31

0.64
1.11
Price/Graham Number 2.73
GMED's Price/Graham Number is ranked higher than
51% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. GMED: 2.73 )
GMED' s 10-Year Price/Graham Number Range
Min: 1.24   Max: 2.32
Current: 2.73

1.24
2.32
Earnings Yield (Greenblatt) 5.10
GMED's Earnings Yield (Greenblatt) is ranked higher than
72% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. GMED: 5.10 )
GMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 15
Current: 5.1

4.5
15

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GM0N.Germany
Globus Medical Inc., was incorporated in Delaware in 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders. It is an engineering-driven company with a history of rapidly developing and commercializing products that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options. All of its products fall into one of two categories: innovative fusion or disruptive technologies. The Company's innovative fusion products address a broad range of spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. These advantages have enabled it to grow its sales at a faster rate than the broader spine industry. It defines disruptive technologies as those that represent a significant shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. The Company's comprehensive REVERE pedicle screw and rod system incorporates a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. Certain other of its products are first-in-class, such as its XPAND and FORTIFY corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from radiolucent polyetheretherketone, or PEEK, to allow for postoperative radiographic visualization. Certain of its other products, such as COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Its significant competitors are Medtronic, DePuy (a division of Johnson & Johnson), Synthes (which is being acquired by Johnson & Johnson), Stryker and NuVasive, which together represent a significant portion of the spine market.
» More Articles for GMED

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide